| Trial ID: | L3787 |
| Source ID: | NCT06099067
|
| Associated Drug: |
Canagliflozin
|
| Title: |
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
|
| Acronym: |
HARRP
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Canagliflozin|DRUG: DPP4 inhibitor|DRUG: Liraglutide|DRUG: Saxagliptin|DRUG: 2nd generation Sulfonylurea
|
| Outcome Measures: |
Primary: 3-point MACE, 3-point MACE: Relative hazard of composite outcome of Stroke, MI, and Mortality, Follow up begins the day after drug initiation for the three investigated studies [a median of 134-167 days] |
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
239990
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2020-05-15
|
| Completion Date: |
2023-08-31
|
| Results First Posted: |
|
| Last Update Posted: |
2024-08-30
|
| Locations: |
Research Site, Gothenburg, 43183, Sweden
|
| URL: |
https://clinicaltrials.gov/show/NCT06099067
|
